scholarly journals A Partial Response of Pulmonary Pleomorphic Carcinoma to Camrelizumab (PD1 Monoclonal Antibody) Monotherapy: A Case Report

2020 ◽  
Vol Volume 13 ◽  
pp. 12471-12476
Author(s):  
Yi Chen ◽  
Hao Zhang ◽  
Junfeng Shi ◽  
Tongshan Wang
Keyword(s):  
Monoclonal Antibody ◽  
Case Report ◽  
Partial Response ◽  
Pleomorphic Carcinoma

scholarly journals A case report of therapeutically challenging chronic actinic dermatitis

2019 ◽  
Vol 7 ◽  
pp. 2050313X1984523 ◽  
Author(s):  
Luvneet Verma ◽  
Melanie Pratt
Keyword(s):  
Monoclonal Antibody ◽  
Atopic Dermatitis ◽  
Mycophenolate Mofetil ◽  
Case Report ◽  
Partial Response ◽  
Low Dose ◽  
Immunosuppressive Agents ◽  
Ultraviolet A ◽  
Chronic Actinic Dermatitis ◽  
Systemic Agents

Chronic actinic dermatitis is a difficult to treat photodermatitis. Treatment is not standardized and involves topical corticosteroids and immunomodulators, and systemic immunosuppressive agents. We present a case with partial response to dupilumab, a monoclonal antibody approved for atopic dermatitis. In recalcitrant cases, systemic agents such as methotrexate, azathioprine, mycophenolate mofetil, and thalidomide, extracorpeal electrophoresis, and low-dose psoralen and ultraviolet A can also be considered.

Subcutaneous auto-administration of trastuzumab following therapeutic education: A case report

2018 ◽  
Vol 25 (6) ◽  
pp. 1523-1525 ◽  
Author(s):  
Marine Deppenweiler ◽  
Marc Debled ◽  
Jean-Luc Robquin ◽  
Barbara Lortal-Canguilhem
Keyword(s):  
Monoclonal Antibody ◽  
Case Report ◽  
Education Program ◽  
Marketing Authorization ◽  
Therapeutic Education ◽  
Breast Cancers ◽  
Self Administration ◽  
Patient’S Experience ◽  
Epidermal Growth

Trastuzumab is a monoclonal antibody used to treat human epidermal growth receptor 2 positive (HER2+) breast cancers either by itself or in combination with other chemotherapy medication. Marketing authorization was granted for a subcutaneous form of the antibody in 2014. In this case report, we discuss our experience with a patient who took part in a therapeutic education program on self-administration of trastuzumab. We demonstrate that these types of self-administered injections are not only possible but also are toxicity-free. Based on the tolerance data and our patient’s experience, we propose that the current regulations be relaxed regarding the availability of trastuzumab subcutaneous form in order to develop a cheaper “city scheme,” i.e. self-administered injections.

scholarly journals A case report of pleomorphic carcinoma of the pancreas.

1988 ◽  
Vol 21 (11) ◽  
pp. 2619-2622
Author(s):  
Hiroaki TSUMURA ◽  
Tetsuhiko MASUDA ◽  
Shigenobu KADO ◽  
Shirou NAKAI ◽  
Nobuo KOUMO ◽  
...  
Keyword(s):  
Case Report ◽  
Pleomorphic Carcinoma ◽  
Carcinoma Of The Pancreas

Leukemic gingival infiltrate as an indicator of chemotherapeutic failure following monoclonal antibody therapy: a case report

2003 ◽  
Vol 23 (3) ◽  
pp. 108-110 ◽  
Author(s):  
Thomas P. Sollecito ◽  
Julia Draznin ◽  
Ernesta Parisi ◽  
Kathleen Duffy ◽  
Edward A. Stadtmauer ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Case Report ◽  
Antibody Therapy ◽  
Monoclonal Antibody Therapy

scholarly journals Gastrointestinal Stromal Tumour with Synchronous Bone Metastases: A Case Report and Literature Review

2017 ◽  
Vol 10 (1) ◽  
pp. 66-76 ◽  
Author(s):  
Philippe Rochigneux ◽  
Lénaig Mescam-Mancini ◽  
Delphine Perrot ◽  
Erwan Bories ◽  
Laurence Moureau-Zabotto ◽  
...  
Keyword(s):  
Case Report ◽  
Partial Response ◽  
Literature Review ◽  
Bone Metastases ◽  
Unusual Case ◽  
Gastrointestinal Stromal Tumour ◽  
Gastric Gist ◽  
Gastrointestinal Stromal Tumours ◽  
Exon 11 ◽  
Mesenchymal Tumours

Gastrointestinal stromal tumours (GISTs) are mesenchymal tumours of the digestive tract, derived from Cajal interstitial cells. Bone metastases are very rare, and there is no consensus regarding their treatment. Here, we present the unusual case of a 66-year-old man with a gastric GIST with synchronous bone and liver metastases, fully documented at the pathological and molecular levels with a KIT exon 11 mutation. After 9 months of imatinib, the scanner showed a 33% partial response of target lesions. We also review the literature and describe the characteristics, treatment, and outcome of all cases previously reported.

Sign in / Sign up

Export Citation Format

Share Document